Krs Pharmaceuticals Private Limited loan details
Charges taken from banks & financial institutesData last updated:
Amount in (₹)
Krs Pharmaceuticals Private Limited has 7 charges registered with the Registrar of Companies: 4 open charges worth Rs 22.51 Cr and 3 satisfied charges worth Rs 9.55 Cr. The lender named on its open charges is Axis Bank Limited. The most recent charge was created on 29 Dec 2023 for Rs 4.98 Cr and is open.
Charges Breakdown by Lending Institutions
- Others : 22.37 Cr
- Axis Bank Limited : 0.14 Cr
₹22.51 crore
₹9.55 crore
4
Others
Modification
31 Jan 2025
₹9.10 cr
| Charge Id | Lender | Amount | Creation Date | Last Modification Date | Satisfaction Date | Status |
|---|---|---|---|---|---|---|
| 10138147 View Details | State Bank Of India | ₹ 8.56 | 12 Jan 2009 | 07 Nov 2016 | 23 Apr 2018 | Satisfied |
| 90126735 View Details | Andhra Pradesh State Financial Corporation | ₹ 0.79 | 01 Sep 2003 | - | 12 Jan 2009 | Satisfied |
| 90126623 View Details | Andhra Pradesh State Financial Corporation | ₹ 0.20 | 08 Nov 2002 | - | 12 Jan 2009 | Satisfied |
| 100872415 View Details | Others | ₹ 4.98 | 29 Dec 2023 | - | - | Open |
| 100766026 View Details | Others | ₹ 9.10 | 27 Jun 2023 | 31 Jan 2025 | - | Open |
| 100475355 View Details | Axis Bank Limited | ₹ 0.14 | 29 Sep 2020 | - | - | Open |
| 100172579 View Details | Others | ₹ 8.29 | 22 Feb 2018 | 24 Dec 2019 | - | Open |
Premium access Charge documents and asset detailsThe filed charge documents and the assets pledged under each charge are in the company report.
Verified entity values are shown only after access is granted. | ||||||
A charge is a security interest a company creates over its assets in favour of a lender. An open charge is still outstanding; a satisfied charge has been repaid and closed with the Registrar. Under the Companies Act, 2013 every charge must be registered within thirty days of creation (Form CHG-1, or CHG-9 for debentures) and its satisfaction reported within thirty days of repayment (Form CHG-4). Amounts are as filed with the MCA.